Portrazza
Active Ingredient(s): NecitumumabFDA Approved: * November 24, 2015
Pharm Company: * ELI LILLY CO
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Portrazza Overview
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4&am...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Necitumumab
Recent Portrazza Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Necitumumab
- Injection: 800mg/50ml
NDC Database Records for Portrazza: (1 result)
Sorted by National Drug Code- 0002-7716 Portrazza 16 mg/ml Intravenous Solution by Eli Lilly and Company